# Solventum (SOLV)

Sector: Medical technology and dental products

| Field | Value |
|---|---|
| Price | $84.51 |
| Market cap | $14B |
| Intrinsic value source | Analysts |
| Data as of | 2026-11-20 |
| Next earnings | 2027-02-25 (estimate) |

Analysts: Leaning bullish

Picks: Research only

Discount category: Pricey

## In short

The market doubts that Solventum can grow faster after its split from 3M while it carries debt and lawsuits, and steady growth with a separation of Health Information Systems that adds value can lift its value.

## Themes and gap

- Themes: High debt (leverage), Regulation and courts (regulation-legal), Tariffs and trade (trade-tariffs)
- Gap type: Can close (closable)
- Why: The Q4 2026 report, expected in late February 2027, and the planned separation of Health Information Systems show whether growth and margins rise after the split from 3M.

## About

Solventum Corporation (Solventum) is based in Eagan, Minnesota. 3M spun it off on April 1, 2024. It makes and sells health care products in three segments: MedSurg, which includes Advanced Wound Care and Infection Prevention and Surgical Solutions, Dental Solutions and Health Information Systems. It sold its Purification and Filtration business to Thermo Fisher Scientific on September 1, 2025, and it bought Acera Surgical in December 2025. Net sales were $1,949 million in Q3 2026 and $6,165 million for nine months. The common stock trades on the NYSE in US dollars. Solventum files 10-K and 10-Q reports.

## Thesis

The price of Solventum depends on whether it can grow faster and widen its margins after its separation from 3M. In Q3 2026 organic sales fell 2.8%, because customers placed advance orders in Q2 before the cutover to a new ERP system, and Solventum has now exited about 90% of its transition service agreements with 3M. For nine months, organic sales grew 2.9% and the adjusted operating income margin rose to 22.8% from 20.7%. Solventum carries $5.1 billion of debt, its 10-Q describes about 8,400 lawsuits about the Bair Hugger warming system, and it plans to separate its Health Information Systems business, which had an operating margin of 40.3% for nine months. For the price to hold or rise, four things must be true. Organic sales growth must reach the high end of the 2026 range of 2.5% to 3.0% and rise in 2027 when the effect of the advance orders ends. The margin must keep rising after the exit from the 3M agreements. Free cash flow must grow from the $200 million to $300 million that Solventum expects for 2026, so that debt can fall. The separation of Health Information Systems must give value to shareholders. The Q4 2026 report, expected in late February 2027, is the next test.

## Checkpoints

- Feb 25, 2027 (estimate): Q4 2026 results and 2027 guidance. Status: Pending. Watch: Adjusted earnings per share for 2026 are in the range of $7.20 to $7.30 and the 2027 guidance shows higher organic growth, and this passes; results below the range fail.
- 2027 (estimate): Separation of Health Information Systems. Status: Pending. Watch: Solventum announces a sale or spin-off of Health Information Systems with terms that lower debt or return value to shareholders, and this passes; a stopped or long delayed separation fails.

## Balance sheet

- Cash: $451M
- Debt: $5.1B
- Net debt: $4.6B
- Undrawn credit line: $2.0B
- Debt due within 12 months: $507M
- Last debt due: 2064

At September 30, 2026, Solventum had cash and cash equivalents of $451 million. Total debt was $5,068 million at carrying value: senior notes due from 2027 to 2064, $110 million on a three-year term loan and $48 million of other borrowings. Debt due within one year was $507 million, which includes $349 million of 5.45% notes due 2027. The $2.0 billion revolving credit facility, which expires in 2029, had no borrowings, and there was no commercial paper. Finance leases of $206 million and pension and postretirement benefits of $355 million are not in the debt tile. Operating cash flow was $215 million for nine months and capital spending was $247 million. Total equity was $4,805 million.

As of 2026-09-30.

Sources:

- https://www.sec.gov/Archives/edgar/data/1964738/000196473826000056/solv-20260930.htm
- https://www.sec.gov/Archives/edgar/data/1964738/000196473826000055/q32026-8kerexx991.htm

## Dividends

Solventum does not pay a dividend.

Source: company filings and market data, read on 2026-11-12.

## Recent events

- 2026-11-05: Solventum reported Q3 2026 results. Net sales fell 7.0% to $1,949 million and organic sales fell 2.8%, because of the reversal of advance orders from Q2. Adjusted diluted earnings per share were $1.45 and the GAAP loss per share was $0.07. Solventum raised its 2026 guidance for adjusted earnings per share to $7.20 to $7.30 and expects organic sales growth near the high end of 2.5% to 3.0%.
- 2026-09-30: In the first nine months of 2026, Solventum repurchased 5.3 million shares for about $403 million under the $1 billion program that the board approved in November 2025.
- 2026-08-05: Solventum announced that it intends to separate its Health Information Systems business. It is evaluating a range of separation pathways.
- 2026-07-16: The board appointed Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer from August 10, 2026. He replaced Mary Wilcox, who retired.
- 2026-06-30: In Q2 2026, Solventum received $55 million from an insurance policy that covers litigation costs that it paid before.

## Latest news and filings

- Last earnings: 2026-11-05 (8-K: https://www.sec.gov/Archives/edgar/data/1964738/000196473826000055/)
- Next earnings: 2027-02-25 (expected; the company has not confirmed it)

| Filed | Form | Headline | Period end | XBRL document | Link |
| --- | --- | --- | --- | --- | --- |
| 2026-11-05 | 10-Q | Quarterly report for the period ended Sep 30, 2026 | 2026-09-30 | solv-20260930 | https://www.sec.gov/Archives/edgar/data/1964738/000196473826000056/solv-20260930.htm |
| 2026-11-05 | 8-K | Earnings release |  | solv-20261105 | https://www.sec.gov/Archives/edgar/data/1964738/000196473826000055/ |
| 2026-08-05 | 10-Q | Quarterly report for the period ended Jun 30, 2026 | 2026-06-30 | solv-20260630 | https://www.sec.gov/Archives/edgar/data/1964738/000196473826000047/solv-20260630.htm |
| 2026-08-05 | 8-K | Earnings release |  | solv-20260805 | https://www.sec.gov/Archives/edgar/data/1964738/000196473826000045/ |
| 2026-08-05 | 8-K | Investor disclosure and Other company news |  | solv-20260805 | https://www.sec.gov/Archives/edgar/data/1964738/000196473826000043/solv-20260805.htm |
| 2026-07-20 | 8-K | Change of directors or officers |  | solv-20260716 | https://www.sec.gov/Archives/edgar/data/1964738/000196473826000038/solv-20260716.htm |
| 2026-06-05 | 8-K | Other company news |  | solv-20260602 | https://www.sec.gov/Archives/edgar/data/1964738/000196473826000036/solv-20260602.htm |
| 2026-05-27 | 8-K | Change of directors or officers |  | solv-20260521 | https://www.sec.gov/Archives/edgar/data/1964738/000196473826000031/solv-20260521.htm |
| 2026-05-20 | 8-K | Shareholder vote results |  | solv-20260515 | https://www.sec.gov/Archives/edgar/data/1964738/000196473826000027/solv-20260515.htm |
| 2026-05-05 | 10-Q | Quarterly report for the period ended Mar 31, 2026 | 2026-03-31 | solv-20260331 | https://www.sec.gov/Archives/edgar/data/1964738/000196473826000024/solv-20260331.htm |

Every filing on SEC EDGAR (CIK 1964738): https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001964738&type=&dateb=&owner=include&count=40

## Risks

- Medium: Product lawsuits can cost money. The 10-Q describes about 8,400 lawsuits in the United States, with 3M as a named defendant, that say the Bair Hugger patient warming system caused surgical site infections.
- Medium: Debt is high. Total debt was $5,068 million at September 30, 2026, and $507 million of it is due within one year.
- Medium: The separation from 3M and the planned separation of Health Information Systems cost money and management time. Restructuring and separation costs helped lower the GAAP operating income margin to 3.5% in Q3 2026.
- Medium: Tariffs and inflation can lower margins. The 10-Q says that the US imposed new tariffs under other laws after the Supreme Court decision on IEEPA tariffs.
- Low: Free cash flow is low. It was negative $32 million for nine months of 2026, and Solventum expects $200 million to $300 million for the year.

## Links

- Page: https://picks.utilarium.app/company/SOLV/
- History of changes: https://picks.utilarium.app/company/SOLV/history/
- JSON with full history: https://picks.utilarium.app/data/company/SOLV.json

> Picks is a personal record of stock picks. It gives general opinions about stocks, including a "Top pick" label. They are not tailored to your needs, goals or risk tolerance. Kevin is not a registered adviser and relies on the general-advice exemption in Canadian securities law (NI 31-103 s.8.25). Do your own research, or ask a registered adviser. Kevin may hold any stock on this site. Prices, intrinsic values and ratings can be delayed or wrong; check the original source. Full disclaimer: /disclaimer/.
